Intravitreal aflibercept injection 2.0mg
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Polypoidal Choroidal Vasculopathy
Conditions
Polypoidal Choroidal Vasculopathy
Trial Timeline
May 1, 2013 → Sep 1, 2016
NCT ID
NCT01871376About Intravitreal aflibercept injection 2.0mg
Intravitreal aflibercept injection 2.0mg is a approved stage product being developed by Regeneron Pharmaceuticals for Polypoidal Choroidal Vasculopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT01871376. Target conditions include Polypoidal Choroidal Vasculopathy.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01871376 | Approved | Completed |
Competing Products
9 competing products in Polypoidal Choroidal Vasculopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Zimura + Eylea | Astellas Pharma | Phase 2 | 52 |
| Avacincaptad Pegol | Astellas Pharma | Phase 2 | 52 |
| Verteporfin Photodynamic Therapy + Ranibizumab | Novartis | Approved | 85 |
| Brolucizumab 6mg + Brolucizumab 6mg | Novartis | Phase 3 | 77 |
| Rescue Intravitreal Aflibercept Injection | Regeneron Pharmaceuticals | Approved | 84 |
| Aflibercept Intravitreous Injection | Bayer | Approved | 82 |
| aflibercept 8 mg | Bayer | Phase 3 | 74 |
| aflibercept | Bayer | Approved | 82 |
| ranibizumab intravitreal injection | Pacific Biosciences | Phase 1 | 25 |